Drugs / Exendin-9
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02287285 | Oct 2014 → Aug 2017 | type 2 diabetes mellitus | Blandine Laferrere | Completed | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT01181986 | Aug 2010 → Dec 2012 | type 2 diabetes mellitus | Carl T. Hayden VA Medical Center | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT01760772 | Feb 2013 → Feb 2015 | heart disorder | David Dalessio | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07224334 Comparator | Dec 2025 → Dec 2027 expected | diabetes mellitus | David D'Alessio, M.D. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Exendin-9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01760772 ↗ |
| Action | Inhibit | “GLP-1 receptor inhibitor exendin-9” NCT01181986 ↗ |
| Modality | Peptide | “a 30 amino acid peptide” NCT07224334 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT07224334 ↗ |